Type 2 Diabetes Treatments and Major Adverse Cardiovascular Events by Age and Sex, Simvastatin with Rifaximin for Decompensated Liver Cirrhosis, Approved vs Off-label Doxepin Formulation Trends and more
Editor’s Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from February 1-7, 2025.
